Artificial intelligence (AI) drug development corporation GALAXIS and drug development corporation HANALL BIOPHARMA will begin joint research to develop a new anti-cancer antibody treatment.
GALAXIS said on the 11th that it plans to precisely design antibody treatments that are difficult to produce using existing methods with AI technology. The goal is to enhance cancer treatment efficacy while minimizing side effects.
The core technology of this joint research is the protein design AI platform 'GALAXIS DESIGN' developed by GALAXIS. The AI, which has learned the structure and properties of proteins, will allow for the design of new antibodies that do not exist in the world from scratch. In fact, GALAXIS received attention in March when it designed new antibodies for six new drug targets. This platform is evaluated as a world-class technology in terms of precision, applicability, and scalability.
HANALL BIOPHARMA is a biotechnology company developing antibody and protein-based therapies, with various clinical experiences and a new drug pipeline in the fields of autoimmune diseases, ophthalmic diseases, and cancer. Recently, its 'batoclimab,' being developed as a treatment for autoimmune diseases, was designated as an orphan drug for thyroid eye disease in Japan, and it has achieved positive results in phase 3 clinical trials for myasthenia gravis.
Suk Cha-ok, representative of GALAXIS, said, "GALAXIS's proprietary AI protein design technology could provide a new solution to drug development challenges that the existing industry has struggled to address," adding, "We expect to achieve meaningful research results through this collaboration."
Ahn Hae-kyung, head of the research headquarters at HANALL BIOPHARMA, noted, "HANALL has continuously pursued innovations in AI-based drug development, and this collaboration is an extension of that strategy," expressing hope that, "Together with GALAXIS, we can further expand the depth and speed of our research."